Heart Disease and Diabetes

 

Medicare Patients Less Likely to be Prescribed GLP-1RAs, SGLT2 Inhibitors than Commercially Insured

February 10, 2021

Data from an analysis of nearly 400k older patients suggests Medicare Advantage beneficiaries were less likely than their counterparts with commercial insurance to be prescribed newer glucose-lowering agents such as GLP-1RAs and SGLT2 inhibitors.

Health Coach-Based Primary Care Programs Linked to Reduced Cardiovascular Risk

February 09, 2021

An intervention implementing the use of a health coach in a primary care setting based on the 2013 AHA/ACC/Task Force for the Management of Overweight and Obesity in Adults guidelines was associated with greater weight loss and improvements in blood glucose levels and HDL-C compared to usual care.

HbA1c Swings After Initial Diabetes Diagnosis Helps Predict CVD Risk

February 06, 2021

An analysis of nearly 30k patients from the LEAD study suggests increased HbA1c variability within the first 2 years of a diabetes diagnosis was associated with a 30-59% increase in risk of incident cardiovascular disease.

A Resident's Perspective: SGLT2 Inhibitors for Primary Prevention

December 08, 2020

A resident from Penn State Hershey Medical Center offers his perspective on the potential of the SGLT2 inhibitor class to transform the treatment of diabetes and cardiovascular disease among patients with diabetes.